The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo

JAMA Dermatology

Volumn 149, Issue 1, 2013, Pages 68-73

  Grimes, Pearl E ^a   Hamzavi, Iltefat ^b   Lebwohl, Mark ^c   Ortonne, Jean Paul ^d   Lim, Henry W ^b  

^a Vitiligo and Pigmentation Institute of Southern California   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AFAMELANOTIDE;

ABDOMINAL CRAMP; ADULT; AFRICAN AMERICAN; ARTICLE; BODY SURFACE; CASE REPORT; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL OBSERVATION; DISEASE DURATION; DIZZINESS; DRUG EFFICACY; DRUG IMPLANT; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HUMAN TISSUE; HYPERPIGMENTATION; MELANOCYTE; MELANOGENESIS; MONOTHERAPY; NAUSEA; PHOTOTHERAPY; PRIORITY JOURNAL; SKIN EXAMINATION; SKIN PIGMENTATION; ULTRAVIOLET B RADIATION; VITILIGO;

ADULT; ALPHA-MSH; CELL DIFFERENTIATION; CELL PROLIFERATION; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MELANOCYTES; MIDDLE AGED; SKIN PIGMENTATION; TIME FACTORS; TREATMENT OUTCOME; ULTRAVIOLET THERAPY; VITILIGO;

EID: 84873417252     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/2013.jamadermatol.386     Document Type: Article

References (27)

1. Grimes PE. White patches and bruised souls: advances in the pathogenesis and treatment of vitiligo. J Am Acad Dermatol. 2004;51(1) (suppl):S5-S7.
2. Grimes PE. Disorders of pigmentation. In: Dale DC, Federman DD, Antman K, et al. ACP Medicine. New York, NY: WebMD; 2012:544-554.
3. Guerra L, Dellambra E, Brescia S, Raskovic D. Vitiligo: pathogenetic hypotheses and targets for current therapies. Curr Drug Metab. 2010;11(5):451-467
4. Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003;16(2):90-100 (Pubitemid 36596954)
5. Spritz RA. Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis. J Invest Dermatol. 2012;132(2):268-273
6. Van Den Boorn JG, Konijnenberg G, Dellemijn TA, et al. Autoimmune destruction of skin melanocytes by perilesionalT cells from vitiligo patients. J Invest Dermatol 2009;129(9):2220-2232
7. Falabella R, Barona MI. Update on skin repigmentation therapies in vitiligo. Pigment Cell Melanoma Res. 2009;22(1):42-65
8. Graham A, Westerhof W, Thody AJ. The expression of α-MSH by melanocytes is reduced in vitiligo. Ann N YAcad Sci. 1999;885(885):470-473
9. Cha YC, Lee HJ, Lee SJ, Na GY, Chung SL. The expression of the α-melanocyte stimulating hormone (a-MSH) and melanocortin-1 receptor (MC1R) in the epidermis of the vitiligo. Korean J Dermatol. 2003;41:690-695 (Pubitemid 37046274)
10. Na GY, Lee KH, Kim MK, Lee SJ, Kim DW, Kim JC. Polymorphisms in the melanocortin-1 receptor (MC1R) and agouti signaling protein (ASIP) genes in Korean vitiligo patients. Pigment Cell Res. 2003;16(4):383-387 (Pubitemid 36950571)
11. Kingo K, Aunin E, Karelson M, et al. Gene expression analysis of melanocortin system in vitiligo. J Dermatol Sci. 2007;48(2):113-122. (Pubitemid 47380249)
12. Abdel-Malek Z, Swope VB, Suzuki I, et al. Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. Proc Natl Acad Sci U S A. 1996;92(5):1789-1793
13. Abdel-Malek Z, Scott MC, Suzuki I, et al. The melanocortin-1 receptor is a key regulator of human cutaneous pigmentation. Pigment Cell Res. 2000;13(suppl 8):156-162.
14. Luger TA, Scholzen TE, Brzoska T, Bohm M. New insights into the functions of α-MSH and related peptides in the immune system. Ann N YAcad Sci. 2003;994:133-140 (Pubitemid 36793859)
15. Minder EI. Afamelanotide. Drugs Future. 2010;35(5):365-372
16. Ortonne JP, Schmitt D, Thivolet J. PUVA-induced repigmentation of vitiligo: scanning electron microscopy of hair follicles. J Invest Dermatol. 1980;74(1):40-42 (Pubitemid 10134598)
17. Ortonne JP, MacDonald DM, Micoud A, Thivolet J. PUVA-induced repigmentation of vitiligo: a histochemical (split-DOPA) and ultrastructural study. Br J Dermatol 1979;101(1):1-12. (Pubitemid 10134309)
18. Horio T. Indications and action mechanisms of phototherapy. J Dermatol Sci 2000;23(suppl 1):S17-S21. (Pubitemid 30182545)
19. Falabella R. Vitiligo and the melanocyte reservoir. Indian J Dermatol. 2009;54(4) 313-318
20. Bohm M, Luger TA, Tobin DJ, Garcfa-Borron JC. Melanocortin receptorligands new horizons for skin biology and clinical dermatology. J Invest Dermatol. 2006 126 (9) 1966-1975
21. Scott MC, Suzuki I, Abdel-Malek ZA. Regulation of the human melanocortin 1 receptor expression in epidermal melanocytes by paracrine and endocrine factors and by ultraviolet radiation. Pigment Cell Res. 2002;15(6):433-439. (Pubitemid 35374625)
22. Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. α-Melanocyte- stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immunemediated inflammatory diseases. Endocr Rev 2008;29(5):581-602.
23. Haylett AK, Nie Z, Brownrigg M, Taylor R, Rhodes LE. Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-α-MSH. Br J Dermatol. 2011;164(2):407-414
24. Pacifico A, Leone G. Photo (chemo) therapy for vitiligo. Photodermatol Photoimmunol Photomed. 2011;27(5):261-277.
25. Osawa M, Egawa G, Mak SS, et al. Molecularcharacterization of melanocyte stem cells in their niche. Development. 2005;132(24):5589-5599. (Pubitemid 43125884)
26. Damian DL, Matthews YJ, Phan TA, Halliday GM. An action spectrum for ultraviolet radiation-induced immunosuppression in humans. Br J Dermatol. 2011 164(3):657-659.
27. Kadekaro AL, Chen J, Yang J, et al. α-Melanocyte-stimulating hormone suppresses oxidative stress through a p53-mediated signaling pathway in human melanocytes. Mol Cancer Res. 2012;10(6) 778-786